{"protocolSection":{"identificationModule":{"nctId":"NCT02684981","orgStudyIdInfo":{"id":"1160.249"},"organization":{"fullName":"Boehringer Ingelheim","class":"INDUSTRY"},"briefTitle":"Patient Convenience Study (RE-SONANCE)","officialTitle":"Non-interventional Study Describing Patients´ Perception on Anticoagulant Treatment and Treatment Convenience When Treated With Pradaxa or Vitamine K Antagonist for Stroke Prevention in Non-Valvular Atrial Fibrillation"},"statusModule":{"statusVerifiedDate":"2019-05","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2015-11-11","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2017-06-01","type":"ACTUAL"},"completionDateStruct":{"date":"2017-06-01","type":"ACTUAL"},"studyFirstSubmitDate":"2015-11-11","studyFirstSubmitQcDate":"2016-02-17","studyFirstPostDateStruct":{"date":"2016-02-18","type":"ESTIMATED"},"resultsFirstSubmitDate":"2018-05-31","resultsFirstSubmitQcDate":"2019-05-22","resultsFirstPostDateStruct":{"date":"2019-07-24","type":"ACTUAL"},"lastUpdateSubmitDate":"2019-05-22","lastUpdatePostDateStruct":{"date":"2019-07-24","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Boehringer Ingelheim","class":"INDUSTRY"}},"descriptionModule":{"briefSummary":"The aim of this non-interventional study is to describe patient's perception of anticoagulant treatment when using Pradaxa to prevent stroke and systemic embolism while suffering from atrial fibrillation (according to its approved indication in the approved dosages of 110 milligrams or 150 milligrams twice daily) in comparison to standard care using Vitamin K Antagonist (VKA)."},"conditionsModule":{"conditions":["Atrial Fibrillation","Stroke"]},"designModule":{"studyType":"OBSERVATIONAL","patientRegistry":false,"designInfo":{"observationalModel":"COHORT","timePerspective":"PROSPECTIVE"},"enrollmentInfo":{"count":9472,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Cohort A - VKA to Pradaxa switcher","description":"Patients with non-valvular atrial fibrillation (NVAF), currently on Vitamin K Antagonist (VKA) therapy, who are switched to Pradaxa."},{"label":"Cohort B - newly assigned to treatment","description":"Newly diagnosed NVAF patients who are treated with VKA or Pradaxa (VKA : Pradaxa = 1:1)."}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Convenience PACT-Q2 Scores at Second and Last Assessment Compared to Baseline Assessment","description":"The individual questions in PACT-Q2 were grouped into two domains, convenience and satisfaction. For each domain, a global score was calculated and used for analysis. The range of the global score is 0-100, with higher score indicating better outcome. The global score is calculated by summing up the individual scores, and then rescaled to 0-100. The PACT-Q2 is to be administered to patients once treatment is ongoing. Due to the non-normality of the data, results presented are for median change instead of mean change in PACT-Q2 scores from baseline (V1) to Initiation stage (V2) and from baseline (V1) to Continuation stage (V3) with full range instead of standard deviation of the differences.","timeFrame":"From baseline up to 210 days"},{"measure":"Satisfaction PACT-Q2 Scores at Second and Last Assessment Compared to Baseline Assessment","description":"The individual questions in PACT-Q2 were grouped into two domains, convenience and satisfaction. For each domain, a global score was calculated and used for analysis. The range of the global score is 0-100, with higher score indicating better outcome. The global score is calculated by summing up the individual scores, and then rescaled to 0-100. The PACT-Q2 is to be administered to patients once treatment is ongoing. Due to the non-normality of the data, results presented are for median change instead of mean change in PACT-Q2 scores from baseline (V1) to Initiation stage (V2) and from baseline (V1) to Continuation stage (V3) with full range instead of standard deviation of the differences.","timeFrame":"From baseline up to 210 days"},{"measure":"Convenience PACT-Q2 Scores at Second and Last Assessment Between Treatment Groups","description":"The individual questions in PACT-Q2 were grouped into two domains, convenience and satisfaction. For each domain, a global score was calculated and used for analysis. The range of the global score is 0-100, with higher score indicating better outcome. The global score is calculated by summing up the individual scores, and then rescaled to 0-100. The PACT-Q2 is to be administered to patients once treatment is ongoing. Due to the non-normality of the data, results presented are for median change instead of mean change in PACT-Q2 scores from baseline (V1) to Initiation stage (V2) and from baseline (V1) to Continuation stage (V3) with full range instead of standard deviation of the differences.","timeFrame":"Day 30 up to Day 210"},{"measure":"Satisfaction PACT-Q2 Scores at Second and Last Assessment Between Treatment Groups","description":"The individual questions in PACT-Q2 were grouped into two domains, convenience and satisfaction. For each domain, a global score was calculated and used for analysis. The range of the global score is 0-100, with higher score indicating better outcome. The global score is calculated by summing up the individual scores, and then rescaled to 0-100. The PACT-Q2 is to be administered to patients once treatment is ongoing. Due to the non-normality of the data, results presented are for median change instead of mean change in PACT-Q2 scores from baseline (V1) to Initiation stage (V2) and from baseline (V1) to Continuation stage (V3) with full range instead of standard deviation of the differences.","timeFrame":"Day 30 up to Day 210"},{"measure":"Characterization of Patients With Respect to Congestive Heart Failure, Hypertension, Age (≥75), Diabetes Mellitus, Stroke/Transient Ischemic Attack (TIA), Vascular Disease, Age 65-75, Sex Category (CHA2DS2-VASc) Score","description":"CHA2DS2-VASc score, are clinical prediction rules for estimating the risk of stroke in patients with non-rheumatic atrial fibrillation (AF), a common and serious heart arrhythmia associated with thromboembolic stroke. Such a score is used to determine whether or not treatment is required with anticoagulation therapy or antiplatelet therapy. CHA2DS2-VASc stroke risk score may range from 0 to 9 with 0 being the best outcome. Score of \\< 2 was considered as low or intermediate risk and score of ≥ 2 was considered as high risk.","timeFrame":"Baseline"},{"measure":"Characterization of Patients With Respect to Hypertension, Abnormal Renal and Liver Function, Stroke, Bleeding History or Predisposition, Labile International Normalized Ratio (INR), Elderly (>65 Years), Drug and Alcohol (HAS-BLED) Score","description":"HAS-BLED is a scoring system developed to assess 1-year risk of major bleeding in patients with atrial fibrillation. A calculated HAS-BLED score is between 0 and 9 and based on eight parameters with a weighted value of 0-2. A high score corresponds to a greater risk, while low score corresponds to a lower risk. Data presented are percentage of patients with high and low risk.","timeFrame":"Baseline"},{"measure":"Characterization of Patients With Respect to Kidney Function (Creatinine Clearance)","description":"Creatinine is a waste product produced by muscles from the breakdown of a compound called creatine. Creatinine is filtered from the blood by the kidneys and released into the urine. A creatinine clearance test measures creatinine levels in both a sample of blood and a sample of urine from a 24-hour urine collection. The results are used to calculate the amount of creatinine that has been cleared from the blood and passed into the urine. Data presented here are geometric mean and confidence interval of creatinine clearance for patients at baseline (V1), initiation stage (V2) and continuation stage (V3).","timeFrame":"Baseline and up to 210 days"},{"measure":"Characterization of Patients With Respect to Comorbidities","description":"Comorbidity is the presence of one or more additional diseases or disorders co-occurring with (that is, concomitant or concurrent with) a primary disease or disorder. Data presented here are percentage of total patients with comorbidities.","timeFrame":"Baseline"},{"measure":"Characterization of Patients With Respect to Concomitant Therapies","description":"Concomitant therapies are two or more drugs used or given at or almost at the same time. The data presented here are percentage of total patients for taking concomitant medication.","timeFrame":"Baseline"},{"measure":"Characterization of Patients With Respect to Dosing of Pradaxa","description":"The data presented in this outcome measure is percentage of patients in both cohorts receiving 110 mg and 150 mg dose of Pradaxa at baseline (V1).","timeFrame":"Baseline and up to 210 days"},{"measure":"Duration in Months of Previous VKA Treatment","description":"The data presented in this outcome measure are Mean (SD) of duration in months of previous VKA treatment in total patients in cohort A.","timeFrame":"Baseline"},{"measure":"Stroke- and/or Bleeding Related Risk Factors in Medical History and at Baseline (Not Applicable)","description":"This endpoint is not assessable as the necessary data was not collected in the database","timeFrame":"Baseline"}],"secondaryOutcomes":[{"measure":"PACT-Q2 Scores at Last Assessment Compared to Second Assessment","description":"The individual questions in PACT-Q2 were grouped into two domains, convenience and satisfaction. For each domain, a global score was calculated and used for analysis. The range of the global score is 0-100, with higher score indicating better outcome. The global score is calculated by summing up the individual scores, and then rescaled to 0-100. Due to the non-normality of the data, results presented here are median change in PACT-Q2 scores between initiation stage (V2) and Continuation stage (V3).","timeFrame":"From 30 days up to 210 days"},{"measure":"Description of PACT-Q1 Items at Baseline","description":"Patients in Cohort B were given PACT-Q1 to assess patients' expectation from Anticoagulation therapy. Following are the seven items from PACT-Q1. The score range is 1-5. Each question is analyzed individually, with higher score indicating better outcome. A1 - How confident are you that your anticoagulant treatment (AT) will prevent blood clots? A2 - Do you expect that your AT will relieve some of the symptoms you experience? A3 - Do you expect that your AT will cause side effects such as minor bruises or bleeding? A4 - How important is it for you to have an AT that is easy to take? A5 - How concerned are you about making mistakes when taking your AT? A6 - How important is it for you to take care of your AT by yourself? A7 - How concerned are you about how much you may have to pay for your AT? For questions A1, A2, A4 and A6, higher score is higher expectations of the treatment and for questions A3, A5 and A7, lower score is higher expectations of the treatment.","timeFrame":"Baseline"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria:\n\nCohort A:\n\n1. A. Written informed consent prior to participation\n2. A. Female and male patients \\>= 18 years of age with a diagnosis of non-valvular atrial fibrillation.\n3. A. At least 3 months of continuous VKA treatment for stroke prevention prior to baseline assessment.\n4. A. Patients switched to Pradaxa according Summary of Product Characteristics and physician's discretion.\n\nOR\n\nCohort B:\n\n1. B. Written informed consent prior to participation.\n2. B. Female and male patients \\>= 18 years of age newly diagnosed with non-valvular atrial fibrillation and no previous treatment for stroke prevention (no use of any oral anticoagulant (OAC) within one year prior to enrolment).\n3. B. Stroke prevention treatment initiated with Pradaxa or VKA according to Summary of Product Characteristics and physician's discretion.\n\nExclusion criteria:\n\n1. Contraindication to the use of Pradaxa or VKA as described in the Summary of Product Characteristics (SmPC).\n2. Patients receiving Pradaxa or VKA for any other condition than stroke prevention in atrial fibrillation.\n3. Current participation in any clinical trial of a drug or device.\n4. Current participation in an European registry on the use of oral anticoagulation in AF.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"],"studyPopulation":"European patients with non valvular atrial fibrillation","samplingMethod":"NON_PROBABILITY_SAMPLE"},"contactsLocationsModule":{"overallOfficials":[{"name":"Boehringer Ingelheim","affiliation":"Boehringer Ingelheim","role":"STUDY_CHAIR"}],"locations":[{"city":"Multiple Locations","country":"Austria"},{"city":"Multiple Locations","country":"Bulgaria"},{"city":"Multiple Locations","country":"Czechia"},{"city":"Multiple Locations","country":"Estonia"},{"city":"Multiple Locations","country":"Hungary"},{"city":"Multiple Locations","country":"Israel"},{"city":"Multiple Locations","country":"Latvia"},{"city":"Multiple Locations","country":"Poland"},{"city":"Multiple Locations","country":"Romania"},{"city":"Multiple Locations","country":"Russian Federation"},{"city":"Multiple Locations","country":"Serbia"},{"city":"Multiple Locations","country":"Slovenia"}]},"referencesModule":{"references":[{"pmid":"33929686","type":"DERIVED","citation":"Vinereanu D, Napalkov D, Bergler-Klein J, Benczur B, Ciernik M, Gotcheva N, Medvedchikov A, Poder P, Simic D, Skride A, Tang W, Trusz-Gluza M, Vesely J. Patient perceptions of anticoagulant treatment with dabigatran or a vitamin K antagonist for stroke prevention in atrial fibrillation according to region and age: an exploratory analysis from the RE-SONANCE study. J Thromb Thrombolysis. 2021 Nov;52(4):1195-1206. doi: 10.1007/s11239-021-02450-2. Epub 2021 Apr 30."}]}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"All patients were screened for eligibility. All enrolled patients met all implemented inclusion/exclusion criteria. Out of 9472 enrolled patients, 7 patients with unknown study treatment were not included in the main analysis set. Total 9465 patients were included in the main analysis set and started the study.","recruitmentDetails":"This is an observational study. Total 9472 patients with Non-Valvular Atrial Fibrillation (NVAF) were enrolled in the study using Vitamin K antagonist (VKA) therapy prior to being switched to Pradaxa® and newly diagnosed with NVAF and initiated Pradaxa® or VKA. Patients were followed up for observational period of approximately 6 months.","groups":[{"id":"FG000","title":"Cohort A","description":"Patients with Non-Valvular Atrial Fibrillation (NVAF) using Vitamin K Antagonist (VKA) therapy prior to being switched to oral dose of Pradaxa® 110 milligram (mg) and Pradaxa® 150 mg hard capsules twice daily containing Dabigatran etexilate (active ingredient: Dabigatran) were included."},{"id":"FG001","title":"Cohort B- Pradaxa®","description":"Newly diagnosed patients with Non-Valvular Atrial Fibrillation (NVAF) and initiated Pradaxa® 110 mg and Pradaxa® 150 mg hard capsules twice daily containing Dabigatran etexilate (active ingredient: Dabigatran) therapy."},{"id":"FG002","title":"Cohort B- VKA","description":"Newly diagnosed patients with Non-Valvular Atrial Fibrillation (NVAF) and initiated Vitamin K Antagonist (VKA) therapy were included."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","comment":"Number of patients started are treated with known treatment.","achievements":[{"groupId":"FG000","numSubjects":"4100"},{"groupId":"FG001","numSubjects":"3179"},{"groupId":"FG002","numSubjects":"2186"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"3860"},{"groupId":"FG001","numSubjects":"2969"},{"groupId":"FG002","numSubjects":"2059"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"240"},{"groupId":"FG001","numSubjects":"210"},{"groupId":"FG002","numSubjects":"127"}]}],"dropWithdraws":[{"type":"Permanently discontinued the treatment","reasons":[{"groupId":"FG000","numSubjects":"157"},{"groupId":"FG001","numSubjects":"161"},{"groupId":"FG002","numSubjects":"110"}]},{"type":"Other","reasons":[{"groupId":"FG000","numSubjects":"83"},{"groupId":"FG001","numSubjects":"49"},{"groupId":"FG002","numSubjects":"17"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"Main Analysis set (MAS): This includes all eligible patients who met inclusion/exclusion crteria with known assigned treatment information.","groups":[{"id":"BG000","title":"Cohort A","description":"Patients with Non-Valvular Atrial Fibrillation (NVAF) using Vitamin K Antagonist (VKA) therapy prior to being switched to oral dose of Pradaxa® 110 milligram (mg) and Pradaxa® 150 mg hard capsules twice daily containing Dabigatran etexilate (active ingredient: Dabigatran) were included."},{"id":"BG001","title":"Cohort B- Pradaxa®","description":"Newly diagnosed patients with Non-Valvular Atrial Fibrillation (NVAF) and initiated Pradaxa® 110 mg and Pradaxa® 150 mg hard capsules twice daily containing Dabigatran etexilate (active ingredient: Dabigatran) therapy."},{"id":"BG002","title":"Cohort B- VKA","description":"Newly diagnosed patients with Non-Valvular Atrial Fibrillation (NVAF) and initiated Vitamin K Antagonist (VKA) therapy were included."},{"id":"BG003","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"4100"},{"groupId":"BG001","value":"3179"},{"groupId":"BG002","value":"2186"},{"groupId":"BG003","value":"9465"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"Years","classes":[{"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"4100"},{"groupId":"BG001","value":"3179"},{"groupId":"BG002","value":"2186"},{"groupId":"BG003","value":"9465"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"70.5","spread":"9.57"},{"groupId":"BG001","value":"68.6","spread":"10.1"},{"groupId":"BG002","value":"68.5","spread":"9.49"},{"groupId":"BG003","value":"69.4","spread":"9.79"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"4100"},{"groupId":"BG001","value":"3179"},{"groupId":"BG002","value":"2186"},{"groupId":"BG003","value":"9465"}]}],"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"1998"},{"groupId":"BG001","value":"1602"},{"groupId":"BG002","value":"1080"},{"groupId":"BG003","value":"4680"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"2102"},{"groupId":"BG001","value":"1577"},{"groupId":"BG002","value":"1106"},{"groupId":"BG003","value":"4785"}]}]}]},{"title":"Race and Ethnicity Not Collected","populationDescription":"Race and Ethnicity were not collected from any participant.","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]}],"categories":[{"measurements":[{"groupId":"BG003","value":"0"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Convenience PACT-Q2 Scores at Second and Last Assessment Compared to Baseline Assessment","description":"The individual questions in PACT-Q2 were grouped into two domains, convenience and satisfaction. For each domain, a global score was calculated and used for analysis. The range of the global score is 0-100, with higher score indicating better outcome. The global score is calculated by summing up the individual scores, and then rescaled to 0-100. The PACT-Q2 is to be administered to patients once treatment is ongoing. Due to the non-normality of the data, results presented are for median change instead of mean change in PACT-Q2 scores from baseline (V1) to Initiation stage (V2) and from baseline (V1) to Continuation stage (V3) with full range instead of standard deviation of the differences.","populationDescription":"Main Analysis set (MAS): This includes all eligible patients who met inclusion/exclusion criteria with known assigned treatment information.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Full Range","unitOfMeasure":"Unit on scale","timeFrame":"From baseline up to 210 days","groups":[{"id":"OG000","title":"Cohort A","description":"Patients with Non-Valvular Atrial Fibrillation (NVAF) using Vitamin K Antagonist (VKA) therapy prior to being switched to oral dose of Pradaxa® 110 milligram (mg) and Pradaxa® 150 mg hard capsules twice daily containing Dabigatran etexilate (active ingredient: Dabigatran) were included."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4100"}]}],"classes":[{"title":"Median change from V1 to V2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3992"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"19.23","lowerLimit":"-67.3","upperLimit":"86.5"}]}]},{"title":"Median change from V1 to V3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3827"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"23.08","lowerLimit":"-82.7","upperLimit":"92.3"}]}]}],"analyses":[{"groupIds":["OG000"],"groupDescription":"Statistical analysis for median change in PACT-Q2 scores from V1 to V2","nonInferiorityType":"OTHER","pValue":"< 0.0001","statisticalMethod":"Wilcoxon (Mann-Whitney)","statisticalComment":"Wilcoxon signed rank test has been used for this analysis"},{"groupIds":["OG000"],"groupDescription":"Statistical analysis for median change in convenience PACT-Q2 scores from V1 to V3","nonInferiorityType":"OTHER","pValue":"< 0.0001","statisticalMethod":"Wilcoxon (Mann-Whitney)","statisticalComment":"Wilcoxon signed rank test has been used for this analysis"}]},{"type":"PRIMARY","title":"Satisfaction PACT-Q2 Scores at Second and Last Assessment Compared to Baseline Assessment","description":"The individual questions in PACT-Q2 were grouped into two domains, convenience and satisfaction. For each domain, a global score was calculated and used for analysis. The range of the global score is 0-100, with higher score indicating better outcome. The global score is calculated by summing up the individual scores, and then rescaled to 0-100. The PACT-Q2 is to be administered to patients once treatment is ongoing. Due to the non-normality of the data, results presented are for median change instead of mean change in PACT-Q2 scores from baseline (V1) to Initiation stage (V2) and from baseline (V1) to Continuation stage (V3) with full range instead of standard deviation of the differences.","populationDescription":"Main Analysis set (MAS): This includes all eligible patients who met inclusion/exclusion criteria with known assigned treatment information.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Full Range","unitOfMeasure":"Unit on scale","timeFrame":"From baseline up to 210 days","groups":[{"id":"OG000","title":"Cohort A","description":"Patients with Non-Valvular Atrial Fibrillation (NVAF) using Vitamin K Antagonist (VKA) therapy prior to being switched to oral dose of Pradaxa® 110 milligram (mg) and Pradaxa® 150 mg hard capsules twice daily containing Dabigatran etexilate (active ingredient: Dabigatran) were included."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4100"}]}],"classes":[{"title":"Median change from V1 to V2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3992"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"17.86","lowerLimit":"-85.7","upperLimit":"78.6"}]}]},{"title":"Median change from V1 to V3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3827"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"21.43","lowerLimit":"-57.1","upperLimit":"85.7"}]}]}],"analyses":[{"groupIds":["OG000"],"groupDescription":"Statistical analysis for median change in satisfaction PACT-Q2 scores from V1 to V2","nonInferiorityType":"OTHER","pValue":"< 0.0001","statisticalMethod":"Wilcoxon (Mann-Whitney)","statisticalComment":"Wilcoxon signed rank test has been used for this analysis"},{"groupIds":["OG000"],"groupDescription":"Statistical analysis for median change in satisfaction PACT-Q2 scores from V1 to V3","nonInferiorityType":"OTHER","pValue":"< 0.0001","statisticalMethod":"Wilcoxon (Mann-Whitney)","statisticalComment":"Wilcoxon signed rank test has been used for this analysis"}]},{"type":"PRIMARY","title":"Convenience PACT-Q2 Scores at Second and Last Assessment Between Treatment Groups","description":"The individual questions in PACT-Q2 were grouped into two domains, convenience and satisfaction. For each domain, a global score was calculated and used for analysis. The range of the global score is 0-100, with higher score indicating better outcome. The global score is calculated by summing up the individual scores, and then rescaled to 0-100. The PACT-Q2 is to be administered to patients once treatment is ongoing. Due to the non-normality of the data, results presented are for median change instead of mean change in PACT-Q2 scores from baseline (V1) to Initiation stage (V2) and from baseline (V1) to Continuation stage (V3) with full range instead of standard deviation of the differences.","populationDescription":"Main Analysis set (MAS): This includes all eligible patients who met inclusion/exclusion criteria with known assigned treatment information.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Full Range","unitOfMeasure":"Unit on scale","timeFrame":"Day 30 up to Day 210","groups":[{"id":"OG000","title":"Cohort B- Pradaxa®","description":"Newly diagnosed patients with Non-Valvular Atrial Fibrillation (NVAF) and initiated Pradaxa® 110 mg and Pradaxa® 150 mg hard capsules twice daily containing Dabigatran etexilate (active ingredient: Dabigatran) therapy."},{"id":"OG001","title":"Cohort B- VKA","description":"Newly diagnosed patients with Non-Valvular Atrial Fibrillation (NVAF) and initiated Vitamin K Antagonist (VKA) therapy were included."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3179"},{"groupId":"OG001","value":"2186"}]}],"classes":[{"title":"V2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2817"},{"groupId":"OG001","value":"2016"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"82.69","lowerLimit":"0.0","upperLimit":"100.0"},{"groupId":"OG001","value":"50.00","lowerLimit":"3.8","upperLimit":"100.0"}]}]},{"title":"V3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2709"},{"groupId":"OG001","value":"1944"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"86.54","lowerLimit":"15.4","upperLimit":"100.0"},{"groupId":"OG001","value":"59.62","lowerLimit":"0.0","upperLimit":"100.0"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Mean change in convenience PACT-Q2 scores between VKA and Pradaxa therapy at initiation stage (V2)","nonInferiorityType":"OTHER","pValue":"< 0.001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Net)","paramValue":"18.377","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.514","estimateComment":"The primary analysis of PACT-Q2 scores was based on the random intercept model, where the matched group is considered as a random effect, the treatment as a fixed effect and the score as the response variable."},{"groupIds":["OG000","OG001"],"groupDescription":"Mean change in convenience PACT-Q2 scores between VKA and Pradaxa therapy at continuation stage (V3)","nonInferiorityType":"OTHER","pValue":"< 0.001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Net)","paramValue":"23.341","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.509","estimateComment":"The primary analysis of PACT-Q2 scores was based on the random intercept model, where the matched group is considered as a random effect, the treatment as a fixed effect and the score as the response variable."}]},{"type":"PRIMARY","title":"Satisfaction PACT-Q2 Scores at Second and Last Assessment Between Treatment Groups","description":"The individual questions in PACT-Q2 were grouped into two domains, convenience and satisfaction. For each domain, a global score was calculated and used for analysis. The range of the global score is 0-100, with higher score indicating better outcome. The global score is calculated by summing up the individual scores, and then rescaled to 0-100. The PACT-Q2 is to be administered to patients once treatment is ongoing. Due to the non-normality of the data, results presented are for median change instead of mean change in PACT-Q2 scores from baseline (V1) to Initiation stage (V2) and from baseline (V1) to Continuation stage (V3) with full range instead of standard deviation of the differences.","populationDescription":"Main Analysis set (MAS): This includes all eligible patients who met inclusion/exclusion criteria with known assigned treatment information.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Full Range","unitOfMeasure":"Unit on scale","timeFrame":"Day 30 up to Day 210","groups":[{"id":"OG000","title":"Cohort B- Pradaxa®","description":"Newly diagnosed patients with Non-Valvular Atrial Fibrillation (NVAF) and initiated Pradaxa® 110 mg and Pradaxa® 150 mg hard capsules twice daily containing Dabigatran etexilate (active ingredient: Dabigatran) therapy."},{"id":"OG001","title":"Cohort B- VKA","description":"Newly diagnosed patients with Non-Valvular Atrial Fibrillation (NVAF) and initiated Vitamin K Antagonist (VKA) therapy were included."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3179"},{"groupId":"OG001","value":"2186"}]}],"classes":[{"title":"V2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2817"},{"groupId":"OG001","value":"2016"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"67.86","lowerLimit":"0.0","upperLimit":"100.0"},{"groupId":"OG001","value":"50.00","lowerLimit":"0.0","upperLimit":"100.0"}]}]},{"title":"V3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2709"},{"groupId":"OG001","value":"1944"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"71.43","lowerLimit":"17.9","upperLimit":"100.0"},{"groupId":"OG001","value":"50.00","lowerLimit":"0.0","upperLimit":"100.0"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Mean change in satisfaction PACT-Q2 scores between VKA and Pradaxa therapy at initiation stage (V2)","nonInferiorityType":"OTHER","pValue":"< 0.001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Net)","paramValue":"15.884","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.388","estimateComment":"The primary analysis of PACT-Q2 scores was based on the random intercept model, where the matched group is considered as a random effect, the treatment as a fixed effect and the score as the response variable."},{"groupIds":["OG000","OG001"],"groupDescription":"Mean change in satisfaction PACT-Q2 scores between VKA and Pradaxa therapy at continuation stage (V3)","nonInferiorityType":"OTHER","pValue":"< 0.001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Net)","paramValue":"19.011","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.408","estimateComment":"The primary analysis of PACT-Q2 scores was based on the random intercept model, where the matched group is considered as a random effect, the treatment as a fixed effect and the score as the response variable."}]},{"type":"PRIMARY","title":"Characterization of Patients With Respect to Congestive Heart Failure, Hypertension, Age (≥75), Diabetes Mellitus, Stroke/Transient Ischemic Attack (TIA), Vascular Disease, Age 65-75, Sex Category (CHA2DS2-VASc) Score","description":"CHA2DS2-VASc score, are clinical prediction rules for estimating the risk of stroke in patients with non-rheumatic atrial fibrillation (AF), a common and serious heart arrhythmia associated with thromboembolic stroke. Such a score is used to determine whether or not treatment is required with anticoagulation therapy or antiplatelet therapy. CHA2DS2-VASc stroke risk score may range from 0 to 9 with 0 being the best outcome. Score of \\< 2 was considered as low or intermediate risk and score of ≥ 2 was considered as high risk.","populationDescription":"Main Analysis set (MAS): This includes all eligible patients who met inclusion/exclusion criteria with known assigned treatment information.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of patients (%)","timeFrame":"Baseline","groups":[{"id":"OG000","title":"Cohort A","description":"Patients with Non-Valvular Atrial Fibrillation (NVAF) using Vitamin K Antagonist (VKA) therapy prior to being switched to oral dose of Pradaxa® 110 milligram (mg) and Pradaxa® 150 mg hard capsules twice daily containing Dabigatran etexilate (active ingredient: Dabigatran) were included."},{"id":"OG001","title":"Cohort B- Pradaxa®","description":"Newly diagnosed patients with Non-Valvular Atrial Fibrillation (NVAF) and initiated Pradaxa® 110 mg and Pradaxa® 150 mg hard capsules twice daily containing Dabigatran etexilate (active ingredient: Dabigatran) therapy."},{"id":"OG002","title":"Cohort B- VKA","description":"Newly diagnosed patients with Non-Valvular Atrial Fibrillation (NVAF) and initiated Vitamin K Antagonist (VKA) therapy were included."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4100"},{"groupId":"OG001","value":"3179"},{"groupId":"OG002","value":"2186"}]}],"classes":[{"title":"High risk (Score >= 2)","categories":[{"measurements":[{"groupId":"OG000","value":"88.3"},{"groupId":"OG001","value":"87.8"},{"groupId":"OG002","value":"91.4"}]}]},{"title":"Low risk (Score < 2)","categories":[{"measurements":[{"groupId":"OG000","value":"5.4"},{"groupId":"OG001","value":"8.2"},{"groupId":"OG002","value":"7.0"}]}]},{"title":"Data not available","categories":[{"measurements":[{"groupId":"OG000","value":"6.3"},{"groupId":"OG001","value":"4.0"},{"groupId":"OG002","value":"1.6"}]}]}]},{"type":"PRIMARY","title":"Characterization of Patients With Respect to Hypertension, Abnormal Renal and Liver Function, Stroke, Bleeding History or Predisposition, Labile International Normalized Ratio (INR), Elderly (>65 Years), Drug and Alcohol (HAS-BLED) Score","description":"HAS-BLED is a scoring system developed to assess 1-year risk of major bleeding in patients with atrial fibrillation. A calculated HAS-BLED score is between 0 and 9 and based on eight parameters with a weighted value of 0-2. A high score corresponds to a greater risk, while low score corresponds to a lower risk. Data presented are percentage of patients with high and low risk.","populationDescription":"Main Analysis set (MAS): This includes all eligible patients who met inclusion/exclusion criteria with known assigned treatment information.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of patients (%)","timeFrame":"Baseline","groups":[{"id":"OG000","title":"Cohort A","description":"Patients with Non-Valvular Atrial Fibrillation (NVAF) using Vitamin K Antagonist (VKA) therapy prior to being switched to oral dose of Pradaxa® 110 milligram (mg) and Pradaxa® 150 mg hard capsules twice daily containing Dabigatran etexilate (active ingredient: Dabigatran) were included."},{"id":"OG001","title":"Cohort B- Pradaxa®","description":"Newly diagnosed patients with Non-Valvular Atrial Fibrillation (NVAF) and initiated Pradaxa® 110 mg and Pradaxa® 150 mg hard capsules twice daily containing Dabigatran etexilate (active ingredient: Dabigatran) therapy."},{"id":"OG002","title":"Cohort B- VKA","description":"Newly diagnosed patients with Non-Valvular Atrial Fibrillation (NVAF) and initiated Vitamin K Antagonist (VKA) therapy were included."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4100"},{"groupId":"OG001","value":"3179"},{"groupId":"OG002","value":"2186"}]}],"classes":[{"title":"High risk (Score >= 3)","categories":[{"measurements":[{"groupId":"OG000","value":"59.2"},{"groupId":"OG001","value":"29.1"},{"groupId":"OG002","value":"31.3"}]}]},{"title":"Low risk (Score < 3)","categories":[{"measurements":[{"groupId":"OG000","value":"31.0"},{"groupId":"OG001","value":"64.8"},{"groupId":"OG002","value":"65.7"}]}]},{"title":"Data not available","categories":[{"measurements":[{"groupId":"OG000","value":"9.7"},{"groupId":"OG001","value":"6.8"},{"groupId":"OG002","value":"2.9"}]}]}]},{"type":"PRIMARY","title":"Characterization of Patients With Respect to Kidney Function (Creatinine Clearance)","description":"Creatinine is a waste product produced by muscles from the breakdown of a compound called creatine. Creatinine is filtered from the blood by the kidneys and released into the urine. A creatinine clearance test measures creatinine levels in both a sample of blood and a sample of urine from a 24-hour urine collection. The results are used to calculate the amount of creatinine that has been cleared from the blood and passed into the urine. Data presented here are geometric mean and confidence interval of creatinine clearance for patients at baseline (V1), initiation stage (V2) and continuation stage (V3).","populationDescription":"Main Analysis set (MAS): This includes all eligible patients who met inclusion/exclusion criteria with known assigned treatment information.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"millilitre per minute (mL/min)","timeFrame":"Baseline and up to 210 days","groups":[{"id":"OG000","title":"Cohort A","description":"Patients with Non-Valvular Atrial Fibrillation (NVAF) using Vitamin K Antagonist (VKA) therapy prior to being switched to oral dose of Pradaxa® 110 milligram (mg) and Pradaxa® 150 mg hard capsules twice daily containing Dabigatran etexilate (active ingredient: Dabigatran) were included."},{"id":"OG001","title":"Cohort B- Pradaxa","description":"Newly diagnosed patients with Non-Valvular Atrial Fibrillation (NVAF) and initiated Pradaxa® 110 mg and Pradaxa® 150 mg hard capsules twice daily containing Dabigatran etexilate (active ingredient: Dabigatran) therapy were included."},{"id":"OG002","title":"Cohort B-VKA","description":"Newly diagnosed patients with Non-Valvular Atrial Fibrillation (NVAF) and initiated Vitamin K Antagonist (VKA) therapy were included."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4100"},{"groupId":"OG001","value":"3179"},{"groupId":"OG002","value":"2186"}]}],"classes":[{"title":"V1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3501"},{"groupId":"OG001","value":"2721"},{"groupId":"OG002","value":"1813"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"73.89","lowerLimit":"73.02","upperLimit":"74.77"},{"groupId":"OG001","value":"76.24","lowerLimit":"75.25","upperLimit":"77.24"},{"groupId":"OG002","value":"71.83","lowerLimit":"70.63","upperLimit":"73.04"}]}]},{"title":"V2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1318"},{"groupId":"OG001","value":"937"},{"groupId":"OG002","value":"603"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"74.59","lowerLimit":"73.17","upperLimit":"76.05"},{"groupId":"OG001","value":"75.27","lowerLimit":"73.71","upperLimit":"76.86"},{"groupId":"OG002","value":"71.86","lowerLimit":"69.87","upperLimit":"73.89"}]}]},{"title":"V3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1539"},{"groupId":"OG001","value":"1070"},{"groupId":"OG002","value":"686"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"72.82","lowerLimit":"71.61","upperLimit":"74.05"},{"groupId":"OG001","value":"74.24","lowerLimit":"72.81","upperLimit":"75.69"},{"groupId":"OG002","value":"71.79","lowerLimit":"69.98","upperLimit":"73.63"}]}]}]},{"type":"PRIMARY","title":"Characterization of Patients With Respect to Comorbidities","description":"Comorbidity is the presence of one or more additional diseases or disorders co-occurring with (that is, concomitant or concurrent with) a primary disease or disorder. Data presented here are percentage of total patients with comorbidities.","populationDescription":"Main Analysis set (MAS): This includes all eligible patients who met inclusion/exclusion criteria with known assigned treatment information.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of patients (%)","timeFrame":"Baseline","groups":[{"id":"OG000","title":"Cohort A","description":"Patients with Non-Valvular Atrial Fibrillation (NVAF) using Vitamin K Antagonist (VKA) therapy prior to being switched to oral dose of Pradaxa® 110 milligram (mg) and Pradaxa® 150 mg hard capsules twice daily containing Dabigatran etexilate (active ingredient: Dabigatran) were included."},{"id":"OG001","title":"Cohort B- Pradaxa®","description":"Newly diagnosed patients with Non-Valvular Atrial Fibrillation (NVAF) and initiated Pradaxa® 110 mg and Pradaxa® 150 mg hard capsules twice daily containing Dabigatran etexilate (active ingredient: Dabigatran) therapy."},{"id":"OG002","title":"Cohort B- VKA","description":"Newly diagnosed patients with Non-Valvular Atrial Fibrillation (NVAF) and initiated Vitamin K Antagonist (VKA) therapy were included."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4100"},{"groupId":"OG001","value":"3179"},{"groupId":"OG002","value":"2186"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"86.4"},{"groupId":"OG001","value":"83.4"},{"groupId":"OG002","value":"90.9"}]}]}]},{"type":"PRIMARY","title":"Characterization of Patients With Respect to Concomitant Therapies","description":"Concomitant therapies are two or more drugs used or given at or almost at the same time. The data presented here are percentage of total patients for taking concomitant medication.","populationDescription":"Main Analysis set (MAS): This includes all eligible patients who met inclusion/exclusion criteria with known assigned treatment information.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of patients (%)","timeFrame":"Baseline","groups":[{"id":"OG000","title":"Cohort A","description":"Patients with Non-Valvular Atrial Fibrillation (NVAF) using Vitamin K Antagonist (VKA) therapy prior to being switched to oral dose of Pradaxa® 110 milligram (mg) and Pradaxa® 150 mg hard capsules twice daily containing Dabigatran etexilate (active ingredient: Dabigatran) were included."},{"id":"OG001","title":"Cohort B- Pradaxa®","description":"Newly diagnosed patients with Non-Valvular Atrial Fibrillation (NVAF) and initiated Pradaxa® 110 mg and Pradaxa® 150 mg hard capsules twice daily containing Dabigatran etexilate (active ingredient: Dabigatran) therapy."},{"id":"OG002","title":"Cohort B- VKA","description":"Newly diagnosed patients with Non-Valvular Atrial Fibrillation (NVAF) and initiated Vitamin K Antagonist (VKA) therapy were included."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4100"},{"groupId":"OG001","value":"3179"},{"groupId":"OG002","value":"2186"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"86.4"},{"groupId":"OG001","value":"83.4"},{"groupId":"OG002","value":"91.2"}]}]}]},{"type":"PRIMARY","title":"Characterization of Patients With Respect to Dosing of Pradaxa","description":"The data presented in this outcome measure is percentage of patients in both cohorts receiving 110 mg and 150 mg dose of Pradaxa at baseline (V1).","populationDescription":"Main Analysis set (MAS): This includes all eligible patients who met inclusion/exclusion criteria with known assigned treatment information.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of patients (%)","timeFrame":"Baseline and up to 210 days","groups":[{"id":"OG000","title":"Cohort A","description":"Patients with Non-Valvular Atrial Fibrillation (NVAF) using Vitamin K Antagonist (VKA) therapy prior to being switched to oral dose of Pradaxa® 110 milligram (mg) and Pradaxa® 150 mg hard capsules twice daily containing Dabigatran etexilate (active ingredient: Dabigatran) were included."},{"id":"OG001","title":"Cohort B","description":"Newly diagnosed patients with Non-Valvular Atrial Fibrillation (NVAF) and initiated Pradaxa® 110 mg and Pradaxa® 150 mg hard capsules twice daily containing Dabigatran etexilate (active ingredient: Dabigatran) therapy were included."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4100"},{"groupId":"OG001","value":"3179"}]}],"classes":[{"title":"Pradaxa 110 mg at V1","categories":[{"measurements":[{"groupId":"OG000","value":"34.9"},{"groupId":"OG001","value":"30.4"}]}]},{"title":"Pradaxa 150 mg at V1","categories":[{"measurements":[{"groupId":"OG000","value":"65.1"},{"groupId":"OG001","value":"69.6"}]}]}]},{"type":"PRIMARY","title":"Duration in Months of Previous VKA Treatment","description":"The data presented in this outcome measure are Mean (SD) of duration in months of previous VKA treatment in total patients in cohort A.","populationDescription":"Main Analysis set (MAS): This includes all eligible patients who met inclusion/exclusion criteria with known assigned treatment information.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Months","timeFrame":"Baseline","groups":[{"id":"OG000","title":"Cohort A","description":"Patients with Non-Valvular Atrial Fibrillation (NVAF) using Vitamin K Antagonist (VKA) therapy prior to being switched to oral dose of Pradaxa® 110 milligram (mg) and Pradaxa® 150 mg hard capsules twice daily containing Dabigatran etexilate (active ingredient: Dabigatran) were included."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4100"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34.00","spread":"39.93"}]}]}]},{"type":"SECONDARY","title":"PACT-Q2 Scores at Last Assessment Compared to Second Assessment","description":"The individual questions in PACT-Q2 were grouped into two domains, convenience and satisfaction. For each domain, a global score was calculated and used for analysis. The range of the global score is 0-100, with higher score indicating better outcome. The global score is calculated by summing up the individual scores, and then rescaled to 0-100. Due to the non-normality of the data, results presented here are median change in PACT-Q2 scores between initiation stage (V2) and Continuation stage (V3).","populationDescription":"Main Analysis set (MAS): This includes all eligible patients who met inclusion/exclusion criteria with known assigned treatment information.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Full Range","unitOfMeasure":"Unit on scale","timeFrame":"From 30 days up to 210 days","groups":[{"id":"OG000","title":"Cohort A","description":"Patients with Non-Valvular Atrial Fibrillation (NVAF) using Vitamin K Antagonist (VKA) therapy prior to being switched to oral dose of Pradaxa® 110 milligram (mg) and Pradaxa® 150 mg hard capsules twice daily containing Dabigatran etexilate (active ingredient: Dabigatran) were included."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4100"}]}],"classes":[{"title":"Convenience PACT-Q2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3820"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.92","lowerLimit":"-80.8","upperLimit":"82.7"}]}]},{"title":"Satisfaction PACT-Q2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3820"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.57","lowerLimit":"-57.1","upperLimit":"85.7"}]}]}],"analyses":[{"groupIds":["OG000"],"groupDescription":"Median convenience and satisfaction PACT-Q2 scores at last assessment compared to second assessment","nonInferiorityType":"OTHER","pValue":"< 0.001","statisticalMethod":"Wilcoxon (Mann-Whitney)","statisticalComment":"Wilcoxon signed rank test has been used for this analysis"}]},{"type":"PRIMARY","title":"Stroke- and/or Bleeding Related Risk Factors in Medical History and at Baseline (Not Applicable)","description":"This endpoint is not assessable as the necessary data was not collected in the database","populationDescription":"Treated set (Necessary data was not collected in the data base)","reportingStatus":"POSTED","timeFrame":"Baseline","groups":[{"id":"OG000","title":"Cohort A","description":"Patients with Non-Valvular Atrial Fibrillation (NVAF) using Vitamin K Antagonist (VKA) therapy prior to being switched to oral dose of Pradaxa® 110 milligram (mg) and Pradaxa® 150 mg hard capsules twice daily containing Dabigatran etexilate (active ingredient: Dabigatran) were included."},{"id":"OG001","title":"Cohort B- Pradaxa®","description":"Newly diagnosed patients with Non-Valvular Atrial Fibrillation (NVAF) and initiated Pradaxa® 110 mg and Pradaxa® 150 mg hard capsules twice daily containing Dabigatran etexilate (active ingredient: Dabigatran) therapy."},{"id":"OG002","title":"Cohort B- VKA","description":"Newly diagnosed patients with Non-Valvular Atrial Fibrillation (NVAF) and initiated Vitamin K Antagonist (VKA) therapy were included."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"type":"SECONDARY","title":"Description of PACT-Q1 Items at Baseline","description":"Patients in Cohort B were given PACT-Q1 to assess patients' expectation from Anticoagulation therapy. Following are the seven items from PACT-Q1. The score range is 1-5. Each question is analyzed individually, with higher score indicating better outcome. A1 - How confident are you that your anticoagulant treatment (AT) will prevent blood clots? A2 - Do you expect that your AT will relieve some of the symptoms you experience? A3 - Do you expect that your AT will cause side effects such as minor bruises or bleeding? A4 - How important is it for you to have an AT that is easy to take? A5 - How concerned are you about making mistakes when taking your AT? A6 - How important is it for you to take care of your AT by yourself? A7 - How concerned are you about how much you may have to pay for your AT? For questions A1, A2, A4 and A6, higher score is higher expectations of the treatment and for questions A3, A5 and A7, lower score is higher expectations of the treatment.","populationDescription":"Main Analysis set (MAS): This includes all eligible patients who met inclusion/exclusion criteria with known assigned treatment information","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of patients (%)","timeFrame":"Baseline","groups":[{"id":"OG000","title":"Cohort B- Pradaxa®","description":"Newly diagnosed patients with Non-Valvular Atrial Fibrillation (NVAF) and initiated Pradaxa® 110 mg and Pradaxa® 150 mg hard capsules twice daily containing Dabigatran etexilate (active ingredient: Dabigatran) therapy."},{"id":"OG001","title":"Cohort B- VKA","description":"Newly diagnosed patients with Non-Valvular Atrial Fibrillation (NVAF) and initiated Vitamin K Antagonist (VKA) therapy were included."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3179"},{"groupId":"OG001","value":"2186"}]}],"classes":[{"title":"A1- Missing","categories":[{"measurements":[{"groupId":"OG000","value":"2.2"},{"groupId":"OG001","value":"2.4"}]}]},{"title":"A1- Not at all","categories":[{"measurements":[{"groupId":"OG000","value":"2.0"},{"groupId":"OG001","value":"3.1"}]}]},{"title":"A1- A little","categories":[{"measurements":[{"groupId":"OG000","value":"9.6"},{"groupId":"OG001","value":"13.0"}]}]},{"title":"A1- Moderately","categories":[{"measurements":[{"groupId":"OG000","value":"27.8"},{"groupId":"OG001","value":"31.9"}]}]},{"title":"A1- A lot","categories":[{"measurements":[{"groupId":"OG000","value":"50.8"},{"groupId":"OG001","value":"43.4"}]}]},{"title":"A1- Extremely","categories":[{"measurements":[{"groupId":"OG000","value":"7.7"},{"groupId":"OG001","value":"6.1"}]}]},{"title":"A2- Missing","categories":[{"measurements":[{"groupId":"OG000","value":"2.2"},{"groupId":"OG001","value":"2.4"}]}]},{"title":"A2- Not at all","categories":[{"measurements":[{"groupId":"OG000","value":"11.6"},{"groupId":"OG001","value":"11.8"}]}]},{"title":"A2- A little","categories":[{"measurements":[{"groupId":"OG000","value":"18.5"},{"groupId":"OG001","value":"23.4"}]}]},{"title":"A2- Moderately","categories":[{"measurements":[{"groupId":"OG000","value":"28.9"},{"groupId":"OG001","value":"31.2"}]}]},{"title":"A2- A lot","categories":[{"measurements":[{"groupId":"OG000","value":"30.9"},{"groupId":"OG001","value":"26.6"}]}]},{"title":"A2- Extremely","categories":[{"measurements":[{"groupId":"OG000","value":"7.9"},{"groupId":"OG001","value":"4.6"}]}]},{"title":"A3- Missing","categories":[{"measurements":[{"groupId":"OG000","value":"2.2"},{"groupId":"OG001","value":"2.4"}]}]},{"title":"A3- Not at all","categories":[{"measurements":[{"groupId":"OG000","value":"17.8"},{"groupId":"OG001","value":"13.2"}]}]},{"title":"A3- A little","categories":[{"measurements":[{"groupId":"OG000","value":"38.4"},{"groupId":"OG001","value":"38.9"}]}]},{"title":"A3- Moderately","categories":[{"measurements":[{"groupId":"OG000","value":"26.9"},{"groupId":"OG001","value":"30.7"}]}]},{"title":"A3- A lot","categories":[{"measurements":[{"groupId":"OG000","value":"12.6"},{"groupId":"OG001","value":"12.0"}]}]},{"title":"A3- Extremely","categories":[{"measurements":[{"groupId":"OG000","value":"2.2"},{"groupId":"OG001","value":"2.6"}]}]},{"title":"A4- Missing","categories":[{"measurements":[{"groupId":"OG000","value":"2.2"},{"groupId":"OG001","value":"2.4"}]}]},{"title":"A4- Not at all","categories":[{"measurements":[{"groupId":"OG000","value":"3.3"},{"groupId":"OG001","value":"2.7"}]}]},{"title":"A4- A little","categories":[{"measurements":[{"groupId":"OG000","value":"5.6"},{"groupId":"OG001","value":"7.3"}]}]},{"title":"A4- Moderately","categories":[{"measurements":[{"groupId":"OG000","value":"16.4"},{"groupId":"OG001","value":"20.5"}]}]},{"title":"A4- A lot","categories":[{"measurements":[{"groupId":"OG000","value":"56.1"},{"groupId":"OG001","value":"53.0"}]}]},{"title":"A4- Extremely","categories":[{"measurements":[{"groupId":"OG000","value":"16.5"},{"groupId":"OG001","value":"14.1"}]}]},{"title":"A5- Missing","categories":[{"measurements":[{"groupId":"OG000","value":"2.2"},{"groupId":"OG001","value":"2.4"}]}]},{"title":"A5- Not at all","categories":[{"measurements":[{"groupId":"OG000","value":"17.3"},{"groupId":"OG001","value":"11.3"}]}]},{"title":"A5- A little","categories":[{"measurements":[{"groupId":"OG000","value":"25.3"},{"groupId":"OG001","value":"23.0"}]}]},{"title":"A5- Moderately","categories":[{"measurements":[{"groupId":"OG000","value":"19.8"},{"groupId":"OG001","value":"27.6"}]}]},{"title":"A5- A lot","categories":[{"measurements":[{"groupId":"OG000","value":"27.2"},{"groupId":"OG001","value":"27.5"}]}]},{"title":"A5- Extremely","categories":[{"measurements":[{"groupId":"OG000","value":"8.2"},{"groupId":"OG001","value":"8.3"}]}]},{"title":"A6- Missing","categories":[{"measurements":[{"groupId":"OG000","value":"2.2"},{"groupId":"OG001","value":"2.4"}]}]},{"title":"A6- Not at all","categories":[{"measurements":[{"groupId":"OG000","value":"3.7"},{"groupId":"OG001","value":"3.2"}]}]},{"title":"A6- A little","categories":[{"measurements":[{"groupId":"OG000","value":"7.9"},{"groupId":"OG001","value":"7.8"}]}]},{"title":"A6- Moderately","categories":[{"measurements":[{"groupId":"OG000","value":"17.3"},{"groupId":"OG001","value":"24.9"}]}]},{"title":"A6- A lot","categories":[{"measurements":[{"groupId":"OG000","value":"52.6"},{"groupId":"OG001","value":"49.8"}]}]},{"title":"A6- Extremely","categories":[{"measurements":[{"groupId":"OG000","value":"16.3"},{"groupId":"OG001","value":"11.9"}]}]},{"title":"A7- Missing","categories":[{"measurements":[{"groupId":"OG000","value":"2.2"},{"groupId":"OG001","value":"2.4"}]}]},{"title":"A7- Not at all","categories":[{"measurements":[{"groupId":"OG000","value":"11.4"},{"groupId":"OG001","value":"8.8"}]}]},{"title":"A7- A little","categories":[{"measurements":[{"groupId":"OG000","value":"14.8"},{"groupId":"OG001","value":"11.1"}]}]},{"title":"A7- Moderately","categories":[{"measurements":[{"groupId":"OG000","value":"31.0"},{"groupId":"OG001","value":"20.9"}]}]},{"title":"A7- A lot","categories":[{"measurements":[{"groupId":"OG000","value":"26.2"},{"groupId":"OG001","value":"36.9"}]}]},{"title":"A7- Extremely","categories":[{"measurements":[{"groupId":"OG000","value":"14.4"},{"groupId":"OG001","value":"20.0"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"From first drug administration, until end of the study, up to 210 days.","description":"An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a medicinal product and which does not necessarily have a causal relationship with this treatment. The safety analysis set including all the patients with actual follow up were used for this analysis.","eventGroups":[{"id":"EG000","title":"Cohort A","description":"Patients with Non-Valvular Atrial Fibrillation (NVAF) using Vitamin K Antagonist (VKA) therapy prior to being switched to oral dose of Pradaxa® 110 milligram (mg) and Pradaxa® 150 mg hard capsules twice daily containing Dabigatran etexilate (active ingredient: Dabigatran) were included.","deathsNumAffected":5,"deathsNumAtRisk":4066,"seriousNumAffected":26,"seriousNumAtRisk":4066,"otherNumAffected":0,"otherNumAtRisk":4066},{"id":"EG001","title":"Cohort B- Pradaxa®","description":"Newly diagnosed patients with Non-Valvular Atrial Fibrillation (NVAF) and initiated Pradaxa® 110 mg and Pradaxa® 150 mg hard capsules twice daily containing Dabigatran etexilate (active ingredient: Dabigatran) therapy.","deathsNumAffected":2,"deathsNumAtRisk":3164,"seriousNumAffected":25,"seriousNumAtRisk":3164,"otherNumAffected":0,"otherNumAtRisk":3164},{"id":"EG002","title":"Cohort B- VKA","description":"Newly diagnosed patients with Non-Valvular Atrial Fibrillation (NVAF) and initiated Vitamin K Antagonist (VKA) therapy were included.","deathsNumAffected":4,"deathsNumAtRisk":2181,"seriousNumAffected":15,"seriousNumAtRisk":2181,"otherNumAffected":0,"otherNumAtRisk":2181},{"id":"EG003","title":"Cohort B","description":"Newly diagnosed patients with Non-Valvular Atrial Fibrillation (NVAF) and initiated Pradaxa® 110 mg and Pradaxa® 150 mg hard capsules twice daily containing Dabigatran etexilate (active ingredient: Dabigatran) or Vitamin K Antagonist (VKA) therapy were included.","deathsNumAffected":6,"deathsNumAtRisk":5345,"seriousNumAffected":40,"seriousNumAtRisk":5345,"otherNumAffected":0,"otherNumAtRisk":5345}],"seriousEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4066},{"groupId":"EG001","numAffected":1,"numAtRisk":3164},{"groupId":"EG002","numAffected":1,"numAtRisk":2181},{"groupId":"EG003","numAffected":2,"numAtRisk":5345}]},{"term":"Acute myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4066},{"groupId":"EG001","numAffected":1,"numAtRisk":3164},{"groupId":"EG002","numAffected":0,"numAtRisk":2181},{"groupId":"EG003","numAffected":1,"numAtRisk":5345}]},{"term":"Atrial fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":4066},{"groupId":"EG001","numAffected":1,"numAtRisk":3164},{"groupId":"EG002","numAffected":2,"numAtRisk":2181},{"groupId":"EG003","numAffected":3,"numAtRisk":5345}]},{"term":"Atrioventricular block","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":4066},{"groupId":"EG001","numAffected":0,"numAtRisk":3164},{"groupId":"EG002","numAffected":0,"numAtRisk":2181},{"groupId":"EG003","numAffected":0,"numAtRisk":5345}]},{"term":"Atrioventricular block complete","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4066},{"groupId":"EG001","numAffected":0,"numAtRisk":3164},{"groupId":"EG002","numAffected":1,"numAtRisk":2181},{"groupId":"EG003","numAffected":1,"numAtRisk":5345}]},{"term":"Cardiac arrest","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":4066},{"groupId":"EG001","numAffected":0,"numAtRisk":3164},{"groupId":"EG002","numAffected":0,"numAtRisk":2181},{"groupId":"EG003","numAffected":0,"numAtRisk":5345}]},{"term":"Cardiac failure","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":4066},{"groupId":"EG001","numAffected":2,"numAtRisk":3164},{"groupId":"EG002","numAffected":1,"numAtRisk":2181},{"groupId":"EG003","numAffected":3,"numAtRisk":5345}]},{"term":"Myocarditis","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4066},{"groupId":"EG001","numAffected":1,"numAtRisk":3164},{"groupId":"EG002","numAffected":0,"numAtRisk":2181},{"groupId":"EG003","numAffected":1,"numAtRisk":5345}]},{"term":"Palpitations","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4066},{"groupId":"EG001","numAffected":0,"numAtRisk":3164},{"groupId":"EG002","numAffected":1,"numAtRisk":2181},{"groupId":"EG003","numAffected":1,"numAtRisk":5345}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4066},{"groupId":"EG001","numAffected":1,"numAtRisk":3164},{"groupId":"EG002","numAffected":0,"numAtRisk":2181},{"groupId":"EG003","numAffected":1,"numAtRisk":5345}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":4066},{"groupId":"EG001","numAffected":1,"numAtRisk":3164},{"groupId":"EG002","numAffected":0,"numAtRisk":2181},{"groupId":"EG003","numAffected":1,"numAtRisk":5345}]},{"term":"Faeces discoloured","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":4066},{"groupId":"EG001","numAffected":0,"numAtRisk":3164},{"groupId":"EG002","numAffected":0,"numAtRisk":2181},{"groupId":"EG003","numAffected":0,"numAtRisk":5345}]},{"term":"Gastrointestinal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":4066},{"groupId":"EG001","numAffected":2,"numAtRisk":3164},{"groupId":"EG002","numAffected":2,"numAtRisk":2181},{"groupId":"EG003","numAffected":4,"numAtRisk":5345}]},{"term":"Haematochezia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":4066},{"groupId":"EG001","numAffected":0,"numAtRisk":3164},{"groupId":"EG002","numAffected":0,"numAtRisk":2181},{"groupId":"EG003","numAffected":0,"numAtRisk":5345}]},{"term":"Ileus","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":4066},{"groupId":"EG001","numAffected":0,"numAtRisk":3164},{"groupId":"EG002","numAffected":0,"numAtRisk":2181},{"groupId":"EG003","numAffected":0,"numAtRisk":5345}]},{"term":"Melaena","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":4066},{"groupId":"EG001","numAffected":0,"numAtRisk":3164},{"groupId":"EG002","numAffected":0,"numAtRisk":2181},{"groupId":"EG003","numAffected":0,"numAtRisk":5345}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":4066},{"groupId":"EG001","numAffected":0,"numAtRisk":3164},{"groupId":"EG002","numAffected":1,"numAtRisk":2181},{"groupId":"EG003","numAffected":1,"numAtRisk":5345}]},{"term":"Chest discomfort","organSystem":"General disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4066},{"groupId":"EG001","numAffected":0,"numAtRisk":3164},{"groupId":"EG002","numAffected":1,"numAtRisk":2181},{"groupId":"EG003","numAffected":1,"numAtRisk":5345}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4066},{"groupId":"EG001","numAffected":1,"numAtRisk":3164},{"groupId":"EG002","numAffected":1,"numAtRisk":2181},{"groupId":"EG003","numAffected":2,"numAtRisk":5345}]},{"term":"Death","organSystem":"General disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":4066},{"groupId":"EG001","numAffected":2,"numAtRisk":3164},{"groupId":"EG002","numAffected":3,"numAtRisk":2181},{"groupId":"EG003","numAffected":5,"numAtRisk":5345}]},{"term":"Sudden death","organSystem":"General disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":4066},{"groupId":"EG001","numAffected":0,"numAtRisk":3164},{"groupId":"EG002","numAffected":0,"numAtRisk":2181},{"groupId":"EG003","numAffected":0,"numAtRisk":5345}]},{"term":"Appendiceal abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4066},{"groupId":"EG001","numAffected":1,"numAtRisk":3164},{"groupId":"EG002","numAffected":0,"numAtRisk":2181},{"groupId":"EG003","numAffected":1,"numAtRisk":5345}]},{"term":"Erysipelas","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":4066},{"groupId":"EG001","numAffected":0,"numAtRisk":3164},{"groupId":"EG002","numAffected":0,"numAtRisk":2181},{"groupId":"EG003","numAffected":0,"numAtRisk":5345}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":4066},{"groupId":"EG001","numAffected":0,"numAtRisk":3164},{"groupId":"EG002","numAffected":0,"numAtRisk":2181},{"groupId":"EG003","numAffected":0,"numAtRisk":5345}]},{"term":"Pseudomembranous colitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4066},{"groupId":"EG001","numAffected":1,"numAtRisk":3164},{"groupId":"EG002","numAffected":0,"numAtRisk":2181},{"groupId":"EG003","numAffected":1,"numAtRisk":5345}]},{"term":"Accidental overdose","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4066},{"groupId":"EG001","numAffected":0,"numAtRisk":3164},{"groupId":"EG002","numAffected":1,"numAtRisk":2181},{"groupId":"EG003","numAffected":1,"numAtRisk":5345}]},{"term":"Femoral neck fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4066},{"groupId":"EG001","numAffected":0,"numAtRisk":3164},{"groupId":"EG002","numAffected":1,"numAtRisk":2181},{"groupId":"EG003","numAffected":1,"numAtRisk":5345}]},{"term":"Head injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":4066},{"groupId":"EG001","numAffected":1,"numAtRisk":3164},{"groupId":"EG002","numAffected":0,"numAtRisk":2181},{"groupId":"EG003","numAffected":1,"numAtRisk":5345}]},{"term":"Periorbital haematoma","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":4066},{"groupId":"EG001","numAffected":0,"numAtRisk":3164},{"groupId":"EG002","numAffected":0,"numAtRisk":2181},{"groupId":"EG003","numAffected":0,"numAtRisk":5345}]},{"term":"Rib fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4066},{"groupId":"EG001","numAffected":1,"numAtRisk":3164},{"groupId":"EG002","numAffected":0,"numAtRisk":2181},{"groupId":"EG003","numAffected":1,"numAtRisk":5345}]},{"term":"Arteriogram coronary","organSystem":"Investigations","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4066},{"groupId":"EG001","numAffected":1,"numAtRisk":3164},{"groupId":"EG002","numAffected":0,"numAtRisk":2181},{"groupId":"EG003","numAffected":1,"numAtRisk":5345}]},{"term":"Blood creatinine increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":4066},{"groupId":"EG001","numAffected":1,"numAtRisk":3164},{"groupId":"EG002","numAffected":0,"numAtRisk":2181},{"groupId":"EG003","numAffected":1,"numAtRisk":5345}]},{"term":"Bone pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":4066},{"groupId":"EG001","numAffected":0,"numAtRisk":3164},{"groupId":"EG002","numAffected":0,"numAtRisk":2181},{"groupId":"EG003","numAffected":0,"numAtRisk":5345}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":4066},{"groupId":"EG001","numAffected":0,"numAtRisk":3164},{"groupId":"EG002","numAffected":0,"numAtRisk":2181},{"groupId":"EG003","numAffected":0,"numAtRisk":5345}]},{"term":"Colon cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4066},{"groupId":"EG001","numAffected":1,"numAtRisk":3164},{"groupId":"EG002","numAffected":0,"numAtRisk":2181},{"groupId":"EG003","numAffected":1,"numAtRisk":5345}]},{"term":"Tumour haemorrhage","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4066},{"groupId":"EG001","numAffected":1,"numAtRisk":3164},{"groupId":"EG002","numAffected":0,"numAtRisk":2181},{"groupId":"EG003","numAffected":1,"numAtRisk":5345}]},{"term":"Aphasia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4066},{"groupId":"EG001","numAffected":1,"numAtRisk":3164},{"groupId":"EG002","numAffected":0,"numAtRisk":2181},{"groupId":"EG003","numAffected":1,"numAtRisk":5345}]},{"term":"Cerebral haemorrhage","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4066},{"groupId":"EG001","numAffected":1,"numAtRisk":3164},{"groupId":"EG002","numAffected":0,"numAtRisk":2181},{"groupId":"EG003","numAffected":1,"numAtRisk":5345}]},{"term":"Cerebral infarction","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4066},{"groupId":"EG001","numAffected":0,"numAtRisk":3164},{"groupId":"EG002","numAffected":1,"numAtRisk":2181},{"groupId":"EG003","numAffected":1,"numAtRisk":5345}]},{"term":"Cerebrovascular disorder","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4066},{"groupId":"EG001","numAffected":0,"numAtRisk":3164},{"groupId":"EG002","numAffected":1,"numAtRisk":2181},{"groupId":"EG003","numAffected":1,"numAtRisk":5345}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":4066},{"groupId":"EG001","numAffected":0,"numAtRisk":3164},{"groupId":"EG002","numAffected":0,"numAtRisk":2181},{"groupId":"EG003","numAffected":0,"numAtRisk":5345}]},{"term":"Facial paralysis","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4066},{"groupId":"EG001","numAffected":1,"numAtRisk":3164},{"groupId":"EG002","numAffected":0,"numAtRisk":2181},{"groupId":"EG003","numAffected":1,"numAtRisk":5345}]},{"term":"Hemiparesis","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4066},{"groupId":"EG001","numAffected":1,"numAtRisk":3164},{"groupId":"EG002","numAffected":0,"numAtRisk":2181},{"groupId":"EG003","numAffected":1,"numAtRisk":5345}]},{"term":"Ischaemic stroke","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":4066},{"groupId":"EG001","numAffected":4,"numAtRisk":3164},{"groupId":"EG002","numAffected":1,"numAtRisk":2181},{"groupId":"EG003","numAffected":5,"numAtRisk":5345}]},{"term":"Transient ischaemic attack","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4066},{"groupId":"EG001","numAffected":2,"numAtRisk":3164},{"groupId":"EG002","numAffected":0,"numAtRisk":2181},{"groupId":"EG003","numAffected":2,"numAtRisk":5345}]},{"term":"Calculus bladder","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4066},{"groupId":"EG001","numAffected":1,"numAtRisk":3164},{"groupId":"EG002","numAffected":0,"numAtRisk":2181},{"groupId":"EG003","numAffected":1,"numAtRisk":5345}]},{"term":"Haematuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":4066},{"groupId":"EG001","numAffected":0,"numAtRisk":3164},{"groupId":"EG002","numAffected":0,"numAtRisk":2181},{"groupId":"EG003","numAffected":0,"numAtRisk":5345}]},{"term":"Renal failure","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":4066},{"groupId":"EG001","numAffected":0,"numAtRisk":3164},{"groupId":"EG002","numAffected":0,"numAtRisk":2181},{"groupId":"EG003","numAffected":0,"numAtRisk":5345}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":4066},{"groupId":"EG001","numAffected":0,"numAtRisk":3164},{"groupId":"EG002","numAffected":0,"numAtRisk":2181},{"groupId":"EG003","numAffected":0,"numAtRisk":5345}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":4066},{"groupId":"EG001","numAffected":0,"numAtRisk":3164},{"groupId":"EG002","numAffected":0,"numAtRisk":2181},{"groupId":"EG003","numAffected":0,"numAtRisk":5345}]},{"term":"Dyspnoea exertional","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":4066},{"groupId":"EG001","numAffected":0,"numAtRisk":3164},{"groupId":"EG002","numAffected":0,"numAtRisk":2181},{"groupId":"EG003","numAffected":0,"numAtRisk":5345}]},{"term":"Cardiac pacemaker insertion","organSystem":"Surgical and medical procedures","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":4066},{"groupId":"EG001","numAffected":0,"numAtRisk":3164},{"groupId":"EG002","numAffected":0,"numAtRisk":2181},{"groupId":"EG003","numAffected":0,"numAtRisk":5345}]},{"term":"Cardioversion","organSystem":"Surgical and medical procedures","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4066},{"groupId":"EG001","numAffected":1,"numAtRisk":3164},{"groupId":"EG002","numAffected":0,"numAtRisk":2181},{"groupId":"EG003","numAffected":1,"numAtRisk":5345}]},{"term":"Left atrial appendage occlusion","organSystem":"Surgical and medical procedures","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4066},{"groupId":"EG001","numAffected":1,"numAtRisk":3164},{"groupId":"EG002","numAffected":0,"numAtRisk":2181},{"groupId":"EG003","numAffected":1,"numAtRisk":5345}]},{"term":"Meningioma surgery","organSystem":"Surgical and medical procedures","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":4066},{"groupId":"EG001","numAffected":0,"numAtRisk":3164},{"groupId":"EG002","numAffected":0,"numAtRisk":2181},{"groupId":"EG003","numAffected":0,"numAtRisk":5345}]},{"term":"Transurethral prostatectomy","organSystem":"Surgical and medical procedures","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4066},{"groupId":"EG001","numAffected":1,"numAtRisk":3164},{"groupId":"EG002","numAffected":0,"numAtRisk":2181},{"groupId":"EG003","numAffected":1,"numAtRisk":5345}]},{"term":"Vascular stent insertion","organSystem":"Surgical and medical procedures","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":4066},{"groupId":"EG001","numAffected":0,"numAtRisk":3164},{"groupId":"EG002","numAffected":0,"numAtRisk":2181},{"groupId":"EG003","numAffected":0,"numAtRisk":5345}]},{"term":"Arteriosclerosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4066},{"groupId":"EG001","numAffected":1,"numAtRisk":3164},{"groupId":"EG002","numAffected":0,"numAtRisk":2181},{"groupId":"EG003","numAffected":1,"numAtRisk":5345}]},{"term":"Haematoma","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4066},{"groupId":"EG001","numAffected":0,"numAtRisk":3164},{"groupId":"EG002","numAffected":1,"numAtRisk":2181},{"groupId":"EG003","numAffected":1,"numAtRisk":5345}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4066},{"groupId":"EG001","numAffected":0,"numAtRisk":3164},{"groupId":"EG002","numAffected":1,"numAtRisk":2181},{"groupId":"EG003","numAffected":1,"numAtRisk":5345}]}]},"moreInfoModule":{"limitationsAndCaveats":{"description":"Improper dose reduction in patients not fulfilling reduction criteria, Selection bias, Missing data, Creatinine clearance in minimals, Antiarrhythmic medication contraindicated to Pradaxa, Unassessable Stroke/bleeding related risk factors endpoint"},"certainAgreement":{"piSponsorEmployee":true,"restrictiveAgreement":false},"pointOfContact":{"title":"Boehringer Ingelheim, Call Center","organization":"Boehringer Ingelheim","email":"clintriage.rdg@boehringer-ingelheim.com","phone":"1-800-243-0127"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2017-11-21","uploadDate":"2018-05-30T00:03","filename":"SAP_000.pdf","size":1154311},{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2015-07-23","uploadDate":"2018-05-30T00:04","filename":"Prot_001.pdf","size":3676734}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14","removedCountries":["Czech Republic"]},"conditionBrowseModule":{"meshes":[{"id":"D000001281","term":"Atrial Fibrillation"}],"ancestors":[{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000001145","term":"Arrhythmias, Cardiac"},{"id":"D000006331","term":"Heart Diseases"},{"id":"D000010335","term":"Pathologic Processes"}],"browseLeaves":[{"id":"M21996","name":"Stroke","relevance":"LOW"},{"id":"M4276","name":"Atrial Fibrillation","asFound":"Atrial Fibrillation","relevance":"HIGH"},{"id":"M4143","name":"Arrhythmias, Cardiac","relevance":"LOW"},{"id":"M9109","name":"Heart Diseases","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"}]},"interventionBrowseModule":{"browseLeaves":[{"id":"M17245","name":"Vitamin K","relevance":"LOW"},{"id":"M17248","name":"Vitamins","relevance":"LOW"},{"id":"M3934","name":"Anticoagulants","relevance":"LOW"},{"id":"M490","name":"Dabigatran","relevance":"LOW"},{"id":"T481","name":"Vitamin K","relevance":"LOW"},{"id":"T450","name":"Menaquinone","relevance":"LOW"},{"id":"T449","name":"Menadione","relevance":"LOW"},{"id":"T452","name":"Naphthoquinone","relevance":"LOW"},{"id":"T458","name":"Phylloquinone","relevance":"LOW"}],"browseBranches":[{"abbrev":"Micro","name":"Micronutrients"},{"abbrev":"Coag","name":"Coagulants"},{"abbrev":"All","name":"All Drugs and Chemicals"},{"abbrev":"AnCoag","name":"Anticoagulants"},{"abbrev":"Vi","name":"Vitamins"}]}},"hasResults":true}